![]() ![]() Yet, it is FDA that allows companies to start mass production and distribution of their products. The main risk in the biotech sector is that getting US Food and Drug Administration (FDA) approval is a complex task. The idea lies in capitalizing on a stock that may rise with financial stability and delivering innovative devices. Despite this, there are multiple reasons for considering this stock a profitable investment, although the risk is quite high. This happened mainly due to the sell-off in the tech sector and delays in the supply of components needed to manufacture Nanox.ARC. ![]() In early 2021, the price reached $90 afterwards, it started going down and then reached its low at $20. Last August, Nano-X Imaging successfully IPO'ed, and its stock went up immediately. Currently, the company's portfolio includes two complementary products: Nanox.ARC, which is X-ray equipment, and Nanox.CLOUD, software. Nano-X Imaging's products use digital technologies for medical imaging. Nano-X Imaging Ltd (NNOX.US) is an Israel based medical startup that focuses on developing X-ray equipment and the appropriate software. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |